HBx protein induces HpSC-like features in hepatocellular carcinoma by activating KDM5B by 王 旭陽 & Wang Xuyang
Xuyang Wang, Naoki Oishi, Tetsuro Shimakami, Taro 
Yamashita, Masao Honda, Seishi Murakami, Shuichi 
Kaneko, Department of Disease Control and Homeostasis, 
Kanazawa University Graduate School of Medical Science, 
Kanazawa 920-8641, Ishikawa, Japan
Naoki Oishi, Tetsuro Shimakami, Taro Yamashita, Masao 
Honda, Shuichi Kaneko, Department of Gastroenterology, 
Kanazawa University Hospital, Kanazawa 920-8641, Ishikawa, 
Japan
Author contributions: Wang X, Oishi N and Shimakami 
T designed the study and contributed to acquisition of data; 
Wang X, Oishi N and Yamashita T contributed to analysis 
and interpretation of data; Wang X and Oishi N contributed to 
drafting of the manuscript; Honda M, Murakami S and Kaneko 
S contributed to critical revision of the manuscript for important 
intellectual content; Wang X and Oishi N contributed to statistical 
analysis; Murakami S and Kaneko S are the guarantors of this 
study.
Supported by Grant-in-Aid for Scientific Research (KAKENHI) 
(C), No. 15K08992 (to Oishi N); and Core-to-Core Program, 
B. Asia-Africa Science Platforms, the Japan Society for the 
Promotion of Science (to Kaneko S).
Conflict-of-interest statement: To the best to our knowledge, 
no conflict of interest exists.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was 
selected by an in-house editor and fully peer-reviewed by external 
reviewers. It is distributed in accordance with the Creative 
Commons Attribution Non Commercial (CC BY-NC 4.0) license, 
which permits others to distribute, remix, adapt, build upon this 
work non-commercially, and license their derivative works on 
different terms, provided the original work is properly cited and 
the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
Manuscript source: Unsolicited manuscript
Correspondence to: Naoki Oishi, MD, PhD, Researcher, 
Department of Disease Control and Homeostasis, Kanazawa 
University Graduate School of Medical Science, Kanazawa 
920-8641, Ishikawa, Japan. ooishi@m-kanazawa.jp
Telephone: +81-76-2652233
Fax: +81-76-2344250
Received: December 31, 2016
Peer-review started: January 3, 2017
First decision: February 9, 2017
Revised: February 28, 2017
Accepted: March 30, 2017 
Article in press: March 30, 2017
Published online: May 14, 2017
Abstract
AIM
To determine the role of hepatitis B virus X protein 
(HBx), HBx in regulating hepatic progenitor cell (HPC)-
like features in hepatocellular carcinoma (HCC) and the 
underlying molecular mechanisms.
METHODS
We used a retrovirus vector to introduce wild type 
HBx or empty vector into HepG2 cells. We then used 
these cells to analyze cell proliferation, senescence, 
transformation, and stem-like features. Gene expression 
profiling was carried out on Affymetrix GeneChip Human 
U133A2.0 ver.2 arrays according to the manufacturer’s 
protocol. Unsupervised hierarchical clustering analysis 
and Class Comparison analysis were performed by 
BRB-Array Tools software Version 4.2.2. A total of 238 
hepatitis B virus (HBV)-related HCC patients’ array data 
were used for analyzing clinical features.
RESULTS
The histone demethylase KDM5B was significantly 
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ORIGINAL ARTICLE
Hepatitis B virus X protein induces hepatic stem cell-like 
features in hepatocellular carcinoma by activating KDM5B
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Shuichi Kaneko
highly expressed in HBV-related HCC cases (P  < 0.01). 
In HBV proteins, only HBx up-regulated KDM5B by 
activating c-myc. Hepatic stem cell (HpSC) markers 
(EpCAM, AFP, PROM1, and NANOG) were significantly 
highly expressed in KDM5B-high HCC cases (P  < 0.01). 
KDM5B played an important role in maintaining HpSC-
like features and was associated with a poor prognosis. 
Moreover, inhibition of KDM5B suppressed spheroid 
formation and cell invasion in vitro .
CONCLUSION
HBx activates the histone demethylase KDM5B and 
induces HPC-like features in HCC. Histone demethylases 
KDM5B may be an important therapeutic target against 
HBV-related HCC cases.
Key words: Hepatitis B virus X protein; Hepatocellular 
carcinoma; KDM5B; Progenitor cell; Tumorigenesis
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Core tip: The role of epigenetic regulation in cancer 
biology has been the subject of several studies. These 
chromatin structure modifiers have been increasingly 
shown to facilitate several steps of cancer progression. 
However, the epigenetic regulation of hepatocellular 
carcinoma has not been elucidated. We assumed that 
multifunctional protein hepatitis B virus X (HBx) protein, 
may affect epigenetic regulation of Hepatocellular 
carcinoma. We showed that HBx activated the histone 
demethylase KDM5B and induced HPC-like features 
in hepatocellular carcinoma (HCC) in this study. Our 
results suggested that histone demethylases may be an 
important therapeutic target against HBV-related HCC 
cases.
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INTRODUCTION
Chronic infection by hepatitis B virus (HBV) affects 
approximately 400 million people worldwide and is 
a leading cause of hepatocellular carcinoma (HCC), 
which is considered the sixth most common cancer in 
the world[1,2]. 
HBV encodes the nonstructural hepatitis B virus X 
(HBx) protein, which is conserved among mammalian 
hepadnaviruses, suggesting an important function. 
HBx is the most critical protein for viral replication in 
hepatocytes and for the development of HCC. HBx is a 
multifunctional protein that has been shown to regulate 
many transcription factors such as nuclear factor-
kappa B, ATF-2, activator protein 1, cAMP response 
element binding protein[3], Ras-Raf mitogen-activated 
protein kinase, extracellular signal-regulated kinase, 
phosphoinositol-3-kinase-protein kinase B/Akt[4], 
and Wnt/beta-catenin pathway[5]. These pathways 
are involved in a range of cellular functions including 
apoptosis, cell proliferation, cell cycle progression, and 
cytokine production. Therefore, it is proposed that 
HBx manipulates these cellular signaling pathways, 
resulting in the transformation of HBV-infected 
hepatocytes. Although extensive studies have focused 
on the roles of HBx in malignant transformation[5-10], 
the molecular mechanisms underlying this process are 
not well elucidated.
KDM5B, which is also known as JARID1B or 
PLU1, is an H3K4me3 histone demethylase that is 
overexpressed in many types of cancer including 
breast[11], prostate[12], bladder[13], and lung cancer[14]. 
Histone modifiers, such as KDM5B, and their associated 
post-translational modifications are thought to be 
central to the determination of embryonic stem 
cell fate[15,16]. Embryonic stem cell pluripotency and 
differentiation depend on the interactions between an 
array of chromatin modifiers and several downstream 
transcription factors. This stem cell epigenetic landscape 
has been implicated in tumor progression and 
chemoresistance.
The central hypothesis we explored here is that 
KDM5B maintains cancer stem cells in HCC.
MATERIALS AND METHODS
Human subjects
For gene expression analysis, we assessed three already 
published cohorts. Cohort 1 was 139 caucasian HCC 
cases. KDM5B expression data were derived from these 
specimens as described. Survival data linking to this 
cohort were kindly provided by Dr. Snorri Thorgeirsson 
at NCI[17]. Cohort 2 was 238 cases who received surgical 
resection of HBV-related HCC at the Liver Cancer 
Institute of Fudan University. Their clinicopathologic 
characteristics and prognostic data were kindly provided 
by Dr. Xin Wei Wang at NCI[16]. Cohort 3 was 89 
Japanese HCC cases who received surgical resection at 
the Kanazawa University Hospital[18].
Cell lines
Human HCC cell lines (HepG2, Huh7 and Hep3B) were 
maintained in Dulbecco’s modified Eagle’s medium 
(Gibco BRL, Gaithersburg, MD) containing 10% fetal 
bovine serum and 1% penicillin-streptomycin. We 
used two immortalized human hepatocyte cell lines, 
TTNT16 cells (in which hTERT was introduced)[19,20] 
and T5B cells [in which the SV40 large T antigen (LT) 
was introduced][21,22]. These cell lines were maintained 
in Dulbecco’s modified Eagle’s medium (Gibco BRL, 
Gaithersburg, MD) containing 10% fetal bovine serum 
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and 1% penicillin-streptomycin.
Real-time reverse-transcription polymerase chain 
reaction analysis
Total RNA was subjected to quantitative real-time 
reverse-transcription polymerase chain reaction 
(RT-PCR). mRNAs were analyzed using TaqMan 
Gene Expression Assays in accordance with the 
manufacturer’s instructions (Applied Biosystems, Foster 
City, CA). All RT reactions were run in a GeneAmp 
PCR 9700 Thermocycler (Applied Biosystems). Probes 
used for the analyses were as follows: KDM5B, 
Hs00981910_m1; MYC, Hs00905030_m1 (Applied 
Biosystems), HBV proteins, shown in Table 1. The 
experiments were performed in triplicate. The TaqMan 
gene assay for actin was used to normalize the relative 
abundance of mRNA.
RNA interference
A small interfering RNA (siRNA) specific to KDM5B 
and a control siRNA were obtained from Nippon Gene. 
siRNA specific for c-Myc and a control siRNA were 
obtained from Invitrogen. Transfection was performed 
with Lipofectamine RNAiMAX (Invitrogen) according to 
the manufacturer’s instructions.
Invasion and cell migration assays
Cell migration and invasion were assessed using 
a Cytoselect 24-Well Cell Migration and Invasion 
Assay (CELL BIOLABS). For migration and invasion 
measurements, transfected Huh7 and Hep3B cells 
were seeded at 5.0 × 105 cells/well. The cells that 
invaded or migrated to the underside of the chamber 
were harvested and measured according to the 
manufacturer’s protocol. Results were determined 
from triplicate wells in three independent experiments 
and expressed as a percentage relative to control.
Spheroid formation assays
For spheroid formation assays, single cell suspensions 
of 2.0 × 103 cells were seeded in 6-well Ultra-Low 
Attachment Microplates (Corning, Corning, NY). The 
number of spheroids was measured at 10-14 d after 
seeding. Invasion assays were performed using BD 
BioCoatTM Matrigel Matrix Cell Culture Inserts and 
Control Inserts (BD Biosciences, San Jose, CA).
Immunohistochemistry analyses
Immunohistochemistry (IHC) was performed using 
Envision+ kits according to the manufacturer’s instructions. 
An anti-KDM5B monoclonal antibody was used for 
detecting KDM5B. The staining area and intensities 
were evaluated in each sample and graded from 0-3 (0, 
0-5%; 1, 5%-25%; 2, 25%-50%; 3, > 50%) and 0-2 
(0, negative; 1, weak; 2, strong), respectively. The 
sum of the area and intensity scores of each marker 
(IHC score) were calculated. Samples were defined 
as marker-positive (IHC score ≥ 3) or -negative (IHC 
score ≤ 2).
Statistical analysis
Mann-Whitney, χ 2, Fisher’s exact, and Kruskal-Wallis 
tests were used to compare the clinicopathologic 
characteristics and gene expression data. The cor-
relation of the gene expression data was evaluated 
by Spearman’s rank correlation coefficient. Kaplan-
Meier survival analysis with the log-rank test was 
performed to compare patients’ survival. All analyses 
were performed using GraphPad Prism software 5.0.1 
(GraphPad Software, San Diego, CA).
RESULTS
KDM5B expression in HBV-related HCC
We performed transcriptomic analysis of 139 
retrospectively collected HCC (cohort 1) patients 
to assess whether KDM5B was associated with 
hepatocarcinogenesis. We evaluated and compared 
the expression of KDM5B in HCC cases developed from 
various backgrounds: chronic hepatitis B, chronic hepatitis 
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Table 1  Real-time reverse-transcription polymerase chain reaction primers and probes designed and used in the experiments
PC-C (core) FW 5' CGAGGCAGGTCCCCTAGAA 3'
RV 5' CGGCGATTGAGACCTTCGT 3'
probe 5'-FAM AGAACTCCCTCGCCTCG MGB-3'
PS-S (surface) FW 5' ACCCCAACAAGGATCATTGG 3'
RV 5' CGAATGCTCCCGCTCCTA 3'
probe 5'-FAM CAGAGGCAAATCAG MGB-3'
HBx FW 5' TGTCAACGACCGACCTTGAG 3'
RV 5' CCCAACTCCTCCCAGTCCTT 3'
probe 5'-FAM CATACTTCAAAGACTGTTTGTT MGB-3'
Pol (polymerase) FW  5'  TCCGCTGCCGATCCAT  3'  
RV 5' GCTGCGAGCAAAACAAGCT 3'
probe 5'-FAM CTGCGGAACTCCT MGB-3'
Pg RNA FW 5' GCTCTGTATCGGGAGGCCTTA 3'
(Pregenomic RNA) RV 5' TGAGTGCTGTATGGTGAGGAGAA 3'
probe 5'-FAM AGTCTCCGGAACATT MGB-3'
Primers and probes for hepatitis B virus (HBV) type C. 
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as MH-HCC). HpSC-HCC had stem cell-like features 
and a poorer prognosis than MH-HCC cases. We 
hypothesized that KDM5B induced hepatic progenitor-
like features in HBV-related HCC cases.
To determine whether KDM5B was functionally 
linked to the HpSC-like phenotype, we analyzed 
representative expression levels of HpSC markers 
in cohort 2 HCC cases. Consistently, HpSC markers, 
such as EpCAM, AFP, PROM1, and NANOG, were more 
abundantly expressed in KDM5B high expression HCC 
cases as compared to KDM5B low expression cases 
(Figure 2A). Moreover, KDM5B levels were positively 
correlated with EpCAM or AFP levels in 238 HCC cases 
(Figure 2B and C). 
 Next, to confirm that HBx upregulated KDM5B and 
HpSC markers in HCC cells, we introduced HBx-wt in 
HepG2 and Huh7 cells and evaluate the expression 
of KDM5B and HpSC markers. Introduction of HBx 
up-regulated the expression of KDM5B, EpCAM, AFP, 
PROM1 and NANOG in these cells (Figure 3A and B). 
In addition, inhibition of KDM5B suppressed cell 
invasion (Figure 4A and B) and spheroid formation 
C, alcoholic liver disease, and nonalcoholic steatohepatitis. 
As shown in Figure 1A, KDM5B was significantly highly 
expressed in HBV-related HCC cases compared to 
other etiological-related HCC cases. Moreover, for HBV 
proteins, only HBx up-regulated KDM5B in HepG2 cells 
and immortalized human hepatocytes (TTNT16 and 
T5b cells) (Figure 1B). These results indicated that HBx 
was associated with HBV-related hepatocarcinogenesis 
through the activation of KDM5B.
To understand the effect of KDM5B on the survival 
of HBV-related HCC cases, we analyzed the microarray 
data of 238 HCC cases (cohort 2). Kaplan-Meier survival 
analysis revealed that the KDM5B high expression 
group had a significantly shorter overall survival (P < 
0.05) and recurrence-free survival (P < 0.05) than the 
KDM5B low expression group (Figure 1C and 1D).
KDM5B regulates hepatic stem cell-like features in HCC
Previously, we identified two HCC subgroups, one 
resembling the gene expression signatures of hepatic 
stem cells (HpSCs) (referred to as HpSC-HCC) and 
































































Figure 1  Heterogeneity of KDM5B expression in various hepatocellular carcinoma cases. A: Expression analysis of KDM5B-based quantitative RT-PCR data 
in 139 HCC samples. The horizontal lines in the boxplots represent the median, the boxes represent the interquartile range, and the whiskers represent the 10th and 
90th percentiles. A nonparametric test was used to compare the 5 patient groups of hepatitis B virus (HBV), hepatitis C virus (HCV), alcoholic liver disease (ALD), 
nonalcoholic steatohepatitis (NASH) and others respectively as indicated by P values; B: Expression of KDM5B gene in HepG2, TTNT16, and T5B cells. HBV proteins 
were introduced into these cells by a retroviral system; C: Kaplan-Meier plot of the overall survival of 238 hepatocellular carcinoma (HCC) cases based on their 
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(Figure 4C) in Hep3B and Huh7 cells. However, KDM5B 
did not affect cell proliferation or apoptosis in these 
cells as measured by 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl-tetrazolium bromide and transferase-
mediated dUTP nick-end labeling assays (data not 
shown). These data indicated that KDM5B is an 
important molecule for maintaining HpSC-like features 
in HBV-related HCC cases.
The available Chip-Seq data (http://genome.ucsc.
edu/) revealed that several transcriptional factors, such 
as c-Myc and TCF, preferentially bound to the immediate 
5′ upstream sequence of the predictive transcription 
initiation site of KDM5B. Moreover, c-Myc is one of the 
transcription factors known to be activated by HBx. To 
determine whether c-Myc regulates KDM5B expression, 
we silenced c-Myc expression with a c-Myc-specific 
siRNA in Hep3B and Huh7 cells. Consistently, we found 
that inhibition of c-Myc resulted in the suppression of 
KDM5B and EpCAM expression (Figure 4D-F). 
KDM5B predicts poor prognosis in HCC cases
We performed IHC analysis of cohort 3 cases. We 
confirmed the nuclear accumulation of KDM5B 
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Figure 2  KDM5B is associated with HpSC markers in hepatocellular carcinoma cases. A: Expression analysis of HpSC markers (EpCAM, AFP, PROM1, 
and NANOG) in cohort 2 cases based on their classification by KDM5B expression; B: Spearman correlation analysis of KDM5B and EpCAM expression data as 
determined by mRNA arrays of cohort 2 cases; C: Spearman correlation analysis of KDM5B and AFP expression in 238 HCC cases.
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Figure 3  Introduction of hepatitis B virus X protein is associated with KDM5B and HpSC markers expression. A: Expression analysis of KDM5B and HpSC 
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evaluating the clinicopathological characteristics of 
EpCAM-positive and -negative HCC cases, we found 
that EpCAM-positive HCCs were associated with 
a significantly high frequency of KDM5B-positive 
cases (Figure 5B). We further identified the survival 
outcome of these cases by Kaplan-Meier survival 
analysis. KDM5B-positive HCCs were associated with 
significantly lower overall survival outcomes within 
three years compared with KDM5B-negative HCCs (P 
< 0.01) (Figure 5C).
DISCUSSION
HBV is the smallest human hepatotropic DNA virus, 
which mainly infects host hepatocytes and causes 
a spectrum of pathological processes from acute 
hepatitis and chronic hepatitis, to serious end-stage 
liver diseases such as hepatic cirrhosis and primary 
HCC. Studies of its epidemiology and natural history 
have shown that approximately 25% of chronic 
hepatitis B patients will develop HCC[23,24]. Although 
the pathogenesis of HBV-related HCC has not been 
identified, many studies have suggested that HBx is 
one of the risk factors and is strongly implicated in 
hepatocarcinogenesis.
The role of epigenetic regulation in cancer biology, 
especially that of the histone lysine demethylases 
(KDMs), has been the subject of several studies[25-27]. 
These chromatin structure modifiers have been 
increasingly shown to facilitate several steps of 
cancer progression[28-30]. Several KDMs have been 
implicated in tumor growth, angiogenesis, invasion, 
metastasis, and tumor-related chemoresistance. 
KDM5B specifically removes methyl residues from 
methylated lysine 4 of histone 3, consequently 
repressing gene transcription. The cancer stem-like 
cell (CSC) hypothesis has drawn much attention[31]. 


























































































































































































































Figure 4  Inactivation of KDM5B is associated with stem-like features. Effect of KDM5B siRNA on KDM5B expression (A); Cell invasion of Huh7 cells transduced 
with KDM5B siRNA as determined by the Boyden chamber cell invasion assay (B); Spheroid formation of Huh7 cells transduced with KDM5B siRNA. A vertical axis 
indicates a total number of spheroids from 1000 cells (C); c-Myc mediated silencing of KDM5B and HpSC markers (D). Effect of c-Myc siRNA on the endogenous 
levels of c-Myc (D), KDM5B (E), and EpCAM (F) in Huh7 cells. 
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renewal, chemotherapy resistance, and metastasis. 
On the basis of the role of KDM5B in cancer stem-
like features, we hypothesized that KDM5B is actively 
involved in the poor prognosis of HCC patients.
In this study, we showed that KDM5B were 
associated with poor prognosis of HBV-related HCC. 
In various HBV proteins, HBx strongly up-regulated 
KDM5B expression in HBV-related HCC cases. 
Moreover, KDM5B expression is associated with 
the increased presence of CSC features, including 
enhanced tumor sphere formation, cell migration, 
and invasion, and is related with poor prognosis. The 
administration of a KDM5B inhibitor suppressed HpSC-
like features in HBV-related cases. Therefore, we 
consider that KDM5B could be a potential therapeutic 
target against HBV-related HCC. Many researchers 
reported that HBx-MYC interaction was associated with 
HBV-related hepatocarcinogenesis[32-34]. However, its 
mechanism is not yet clear. Our results indicated that 
KDM5B was a central molecule of HBx-MYC introduced 
hepatocarcinogenesis.
Recently, Wang et al[35] reported that KDM5B 
affected the poor prognosis of HCC cases through 
regulating p15 and p27. Similarly, in the present 
study, KDM5B was related to the poor prognosis of 
HCC patients. Our data show that KDM5B, which is 
activated by HBx, is a useful marker for poor prognosis 
in HBV-related HCC cases. Moreover, we demonstrated 
the possibility that suppression of KDM5B may improve 
the poor phenotype of HBV-related HCCs. 
Our new knowledge is useful for the diagnosis of 
severe HCC patients. Histone demethylases KDM5B 
may be an important therapeutic target against HBV-
related HCC cases.
 In conclusion, HBx induced HpSC-like features 
in hepatocellular carcinoma by activating KDM5B. 
Moreover, HBx and KDM5B interaction related poor 
prognosis of hepatocellular carcinoma cases.
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The role of epigenetic regulation in cancer biology has been the subject of 
several studies. These chromatin structure modifiers have been increasingly 
shown to facilitate several steps of cancer progression. However, the epigenetic 
regulation of hepatocellular carcinoma has not been elucidated.
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Previous study showed that KDM5B affected the poor prognosis of 
hepatocellular carcinoma (HCC) cases through regulating p15 and p27. 
However, the relation between HCC background and KDM5B has not yet clear.
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Figure 5  KDM5B protein expression is associated with EpCAM protein expression and poor prognosis. A: Photographs of immunohistochemistry staining with 
anti-KDM5B and EpCAM antibodies in 89 Japanese hepatocellular carcinoma (HCC) cases; B: Summary of KDM5B and EpCAM expression; C: Kaplan-Meier plot of 
overall survival of cohort 3 cases based on their classification by KDM5B expression.
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useful marker for poor prognosis in HBV-related HCC cases. Moreover, the 
authors demonstrated the possibility that suppression of KDM5B may improve 
the poor phenotype of HBV-related HCCs.
Applications
HBx activated the histone demethylase KDM5B and induced hepatic progenitor 
cell (HPC)-like features in HCC. Presented results suggested that histone 
demethylases may be an important therapeutic target against HBV-related HCC 
cases.
Peer-review
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and induces HPC-like features in HCC. This is the first study evaluating that 
KDM5B, which is activated by HBx, a useful marker for poor prognosis in 
HBV-related HCC cases. Moreover, they demonstrated the possibility that 
suppression of KDM5B may improve the poor phenotype of HBV-related HCCs.
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